Experienced in Granulomatous Hypophysitis

Tomoaki Morioka

Osaka, JP 
Experienced in Granulomatous Hypophysitis
Osaka, JP 
OverviewLocationsClinical Research

Overview

Tomoaki Morioka practices in Osaka, Japan. Mr. Morioka is rated as an Experienced expert by MediFind in the treatment of Granulomatous Hypophysitis. His top areas of expertise are Type 2 Diabetes (T2D), Atherosclerosis, Obesity, and Diabetic Nephropathy.

His clinical research consists of co-authoring 103 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Granulomatous Hypophysitis.

Gender
Male

Locations

Osaka, 5458585, Japan
Other Locations
Asahi, 5458585, Japan
Sumiyoshi, 5588585, Japan
Asahimachi, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Drug
Study Drugs: Dulaglutide, Biguanide (BG), Sulfonylurea (SU), Alpha-Glucosidase Inhibitors (?-GI), Thiazolidinedione (TZD), Glinides (GLN), Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i)
Study Phase: Phase 3

103 Total Publications

Correction: Estimated T50 calciprotein crystallization test in patients undergoing hemodialysis: Osaka Dialysis Complication Study (ODCS).
Correction: Estimated T50 calciprotein crystallization test in patients undergoing hemodialysis: Osaka Dialysis Complication Study (ODCS).
Journal: Clinical and experimental nephrology
Published: September 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Morioka's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile